Sucampo Pharmaceuticals (Sucampo Pharmaceuticals) 3-Year Book Growth Rate : 0.00% (As of Sep. 2017)

View and export this data going back to 2007. Start your Free Trial

What is Sucampo Pharmaceuticals 3-Year Book Growth Rate?

Sucampo Pharmaceuticals's Book Value per Share for the quarter that ended in Sep. 2017 was $0.85.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

Competitive Comparison of Sucampo Pharmaceuticals's 3-Year Book Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Sucampo Pharmaceuticals's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sucampo Pharmaceuticals's 3-Year Book Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sucampo Pharmaceuticals's 3-Year Book Growth Rate distribution charts can be found below:

* The bar in red indicates where Sucampo Pharmaceuticals's 3-Year Book Growth Rate falls into.

Sucampo Pharmaceuticals 3-Year Book Growth Rate Calculation

This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

Sucampo Pharmaceuticals (NAS:SCMP) 3-Year Book Growth Rate Explanation

Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.

Sucampo Pharmaceuticals 3-Year Book Growth Rate Related Terms

Thank you for viewing the detailed overview of Sucampo Pharmaceuticals's 3-Year Book Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Sucampo Pharmaceuticals (Sucampo Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sucampo Pharmaceuticals Inc (NAS:SCMP) » Definitions » 3-Year Book Growth Rate

Traded in Other Exchanges

N/A

Address

Website

http://www.sucampo.com

Sucampo Pharmaceuticals Inc is a part of the healthcare sector in the United States. As a global pharmaceutical company, it commercializes drugs for the treatment of various gastrointestinal, ophthalmic and oncology-based inflammatory disorders. It currently generates revenue mainly from product royalties, product sales, upfront and milestone payments, and reimbursements for development activities.

Executives

Peter Greenleaf	officer: Chief Executive Officer	ONE MEDIMMUNE WAY, GAITHERSBURG MD 20878
Maureen Oconnell	director
Karen L. Smith	director	C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2
Jones W. Bryan	officer: Sr. Vice Pres., BD & Licensing	C/O SUPERNUS PHARMACEUTICALS, INC., 1550 EAST GUDE DRIVE, ROCKVILLE MD 20850
Robert J. Spiegel	director	C/O GERON CORPORATION, 230 CONSTITUTION DRIVE, MENLO PARK CA 94025
Timothy P Walbert	director	1033 SKOKIE BOULEVARD, SUITE 355, NORTHBROOK IL 60062
Peter A Kiener	officer: Chief Science Officer	40 GUEST STREET, BOSTON MA 02135
John Johnson	director	DENDREON CORPORATION, 1301 2ND AVENUE, SEATTLE WA 98101
Peter P. Pfreundschuh	officer: CFO	C/O IMMUNOMEDICS, INC., 300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950
Paul R Edick	director	C/O NEWLINK GENETICS CORP., 2503 SOUTH LOOP DR., SUITE 5100, AMES IA 50010
Thomas J Knapp	other: Former Officer	4640 SW MACADAM AVE., SUITE 270, PORTLAND OR 97239
William Ashton	director	C/O HARRISON CONSULTING GROUP, PO BOX 283, NEWTOWN SQUARE PA 19073
Timothy I Maudlin	director	18739 VOGEL FARM TRAIL, EDEN PRAIRIE MN 55347
Nantahala Capital Management, Llc	10 percent owner	130 MAIN ST., 2ND FLOOR, NEW CANAAN CT 06840
Mariam E Morris	officer: Chief Acctg. Officer, Treas.	C/O SUCAMPO PHARMACEUTICALS, 4520 EAST-WEST HIGHWAY, SUITE 300, BETHESDA MD 20814